Pre-revenue applied research programme — commercial thesis under independent validation
The ten commercial theses on the homepage are anchored to peer-reviewed literature and industry sources. Investors may request access to a restricted data room containing the project dossier, stage-gate documentation, risk register, financial model and IP / confidentiality framework. Access is by application, NDA and Project Lead approval.
statements
Statements on this page that are not historical fact — including descriptions of plans, expected outcomes, market sizing, cost trajectories, valuation comparables, certification timelines and any other forward-looking matter — are forward-looking statements. They reflect current expectations, are subject to material risks and uncertainties (including those listed in the residual-uncertainty register below), and are not guarantees of future performance, certification, regulatory approval or financial outcome. Forward-looking statements are made as at 23 May 2026 and INFORM is under no obligation to update them. Nothing on this site constitutes an offer or solicitation of securities, financial product advice, taxation advice or accounting advice. Refer to ASIC RG 170 (Prospective financial information) and RG 228 (Prospectuses) for general guidance applicable to forward-looking statements in Australia.
What investors see today
Programme postureStage 1 — Pre-Laboratory Activation. Lab execution on NO-GO / HOLD until M1–M4 evidence gates are closed. Plausible Australian TRL position: 3–4, rising toward 5 with field demonstration.
Mechanisms drawn from peer-reviewed literature; INFORM-specific outcomes are validation targets. The controlled INFORM research brief (21 May 2026) consolidates the evidence base across seven domains.
DMAIC / DFSS framing, BABOK alignment, ISO-aligned (not certified) document and configuration controls, and a maintained risk register.
Detailed formulation, dispersion, electrode, DAQ and software-design parameters, supplier identities and the full financial model are confidential and provided only under NDA via the data room.
Ten theses, ten validation handoffs
The investor view of the same ten commercial theses presented on the homepage, with each thesis matched to its literature anchor and the work package / milestone / stage that will independently validate it.
How an investor enquiry proceeds
Diligence pathwaySubmit a data-room access request via the access form, identifying organisation, role, jurisdiction and intended use.
Project Lead triages within one Australian business day.
Counterparty NDA issued and executed.
Restricted Project Dossier, Validation Roadmap, Risk Register and high-level Financial Model summary released.
Briefing call scheduled, including independent review references and stage-gate evidence walkthrough.
Further documents (Six Sigma Design Review v2, CRC-P Submission Pack v2, partner contributions, IP/FTO) released in tranches as diligence progresses.
What this opportunity does not yet resolve
Residual-uncertainty register, carried from the controlled brief.
No independent replication of Tour-lab flash-graphene economics at >100 t/yr.
No commercially certified self-sensing concrete product despite 15 years of research.
2–4× spread in SHM market forecasts.
No Australian standard specifically addresses nano-additives to AS 3600 concrete.
Long-term environmental stability of graphene-cement gauge factor under Australian coastal / freeze-thaw conditions is not yet established at field scale.
Not advice
No statement on this site constitutes an offer or solicitation of securities. INFORM is not a registered managed investment scheme and does not provide financial product advice. Forward-looking statements are subject to evidence verification, WHS approval, partner availability, funding and standards alignment. Past or external literature performance is not indicative of INFORM-specific outcomes. Environmental claims (including any reference to CO₂ reduction potential) are statements of literature-supported potential pending project LCA under ISO 14040/14044 and do not constitute representations of carbon-credit eligibility under any compliance or voluntary scheme.